In individuals with type 2 diabetes in whom diabetes was inadequately managed by GLP-1 RA therapy with or without additional oral glucose-lowering medications, once-weekly IcoSema demonstrated statistical superiority to semaglutide 1.0 mg with respect to HbA1c reduction from baseline to week 52. This evidence concerns the gene GCG and type 2 diabetes mellitus.